Nkgen Biotech, INC 8-K filings

NKGen Biotech, Inc. has amended its equity and business loan agreement with BDW Investments, LLC, modifying security interests and lien provisions.

NKGen Biotech entered into a third amendment to its secured convertible loan agreement, securing $2.42 million in additional funding.

NKGen Biotech entered into a second amendment to its secured convertible loan agreement, securing $412,500 in additional funding.

NKGen Biotech, Inc. has amended its secured convertible loan agreement, securing an additional $607,200 loan and issuing a new warrant, alongside a voting agreement to increase authorized shares.

NKGen Biotech has entered into a $39.9 million secured convertible loan agreement to refinance existing debt and provide additional working capital.

NKGen Biotech, Inc. amended its secured promissory note with AlpineBrook Capital GP I Limited, securing an additional $343,000 in funding, increasing the total principal to $27,101,106.

NKGen Biotech, Inc. amended its secured promissory note with AlpineBrook Capital GP I Limited, increasing its principal debt by $251,000 to a total of $26,758,106.

NKGen Biotech, Inc. amended its secured promissory note with AlpineBrook Capital GP I Limited, securing an additional $295,000 loan and increasing its total principal debt to $26,135,106.

NKGen Biotech and its subsidiary secured a $25.8 million secured promissory note from AlpineBrook Capital, consolidating prior advances and adding new capital, with significant collateral and restrictive covenants.

NKGen Biotech, Inc. has entered into a consulting agreement with Dr. Yong Man Kim, who will continue to serve as Chief Scientific Officer in an independent contractor capacity.

NKGen Biotech has entered into a stock purchase agreement with Asia Advisors Limited, raising $2.5 million through the sale of common stock and issuing significant warrants.

NKGen Biotech finalizes acquisition of NKMax, gaining control of global manufacturing, IP, and commercialization rights.

NKGen Biotech, Inc. has entered into a strategic collaboration agreement with HekaBio K.K., including a $2 million equity investment, to accelerate the development and commercialization of its novel NK cell therapy, troculeucel, for neurodegenerative and autoimmune conditions in Japan.

NKGen Biotech, Inc. announced a $2 million private placement with Japanese strategic investor HekaBio K.K. to fund operations and regain SEC reporting compliance, while facing a temporary move to the OTC Expert Market due to filing delays.

NKGen Biotech, Inc. announced that NKMAX Co., Ltd. stakeholders have approved the Conditional Investment Agreement, paving the way for the acquisition of a majority interest in NKMAX, expected to close in early August 2025.

NKGen Biotech entered into a stock purchase agreement with CFIC-2015 NV Family Investments, LLC, for an aggregate purchase price of $2.5 million, involving the issuance of common stock and warrants.

NKGen Biotech's CEO, Paul Y. Song, invests $2.65 million to accelerate the Phase 2 clinical trial for Alzheimer's disease and meet financial obligations.

NKGen Biotech issues common stock to Kepos Alpha Master Fund to satisfy warrant exercises and downside protection obligations.

NKGen Biotech modifies its loan agreement with East West Bank, extending the maturity date to January 15, 2027, and adjusting the interest rate and payment schedule.

NKGen Biotech entered into a convertible loan agreement for up to $5 million with AlpineBrook Capital to refinance existing debt and issued warrants and shares as consideration.

NKGen Biotech stockholders approved a reverse stock split at a special meeting, with the board later deciding on a 1-for-6 ratio.

NKGen Biotech has regained compliance with Nasdaq's market value of publicly held shares requirement after a period of non-compliance.

NKGen Biotech has amended its forward purchase agreement with Meteora Capital, extending the valuation date to December 31, 2025, and has been selected as the preferred bidder for NKMAX Co. Ltd.

NKGen Biotech has entered into a convertible loan agreement for up to $4.5 million, issuing warrants and shares as part of the deal.

NKGen Biotech awarded significant stock options to its CEO and interim CFO in recognition of their contributions and compensation deferrals due to the company's financial difficulties.

NKGen Biotech has received a notice from Nasdaq for not meeting the minimum market value of publicly held shares requirement, placing it at risk of delisting.

NKGen Biotech has been selected as the stalking horse bidder to acquire NKMax, a South Korean biotech company, in a court-managed rehabilitation process, potentially securing global IP rights for its cell therapy.

NKGen Biotech received a notice from Nasdaq for failing to file its quarterly report on time, but was granted a temporary exception until January 7, 2025.

NKGen Biotech has conducted a group layoff of 16 employees as part of its cost-reduction efforts, resulting in an estimated $93,496 in severance costs.

NKGen Biotech has placed 19 employees on furlough as part of cost-reduction efforts, effective October 27, 2024.